辉瑞公司公布的25价肺炎球菌结合疫苗二期临床数据显示出强劲的免疫原性。其中,针对血清3型的免疫应答得到了增强。该疫苗的保护范围覆盖了25种血清型,展现出更广泛的保护潜力。
辉瑞公司公布的25价肺炎球菌结合疫苗二期临床数据显示出强劲的免疫原性。其中,针对血清3型的免疫应答得到了增强。该疫苗的保护范围覆盖了25种血清型,展现出更广泛的保护潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.